The potential of genetic medicines has never been greater, spanning gene therapies capable of curing fatal orphan diseases to highly adaptable vaccines with pandemic-ending abilities. Driving this era of innovation is an ever-expanding genetic medicines toolbox, highlighted by technologies like adeno-associated viruses (AAV), lipid nanoparticles (LNP), anti-sense oligonucleotides (ASO), RNA interference (RNAi), messenger RNA (mRNA), CRISPR, base editors, RNA-editors, and cell therapies, among others. As this diverse array of technology continues to be coupled with a greater understanding of underlying genetics and pathogenesis of disease, creative solutions to previously incomprehensible biological problems feel attainable. As such, LifeSci Partners is pleased to host a selection of some of the most dynamic companies pioneering genetic medicines, who will have the opportunity to present to our extensive global network of investors and potential strategic partners.